Reference product in bioequivalence [Regulatives / Guidelines]

posted by slebr – Belgium, 2020-11-04 11:02 (874 d 06:10 ago) – Posting: # 22055
Views: 895

Dear Helmut,

first of all, i hope that you are doing well in these trouble period!

we would like to perform a bioequivalence (in Europe) study with our test versus a European marketed reference.

As stated in the guideline:
"For Article 10(1) and 10(3) marketing authorisation applications reference must be made to the dossier of a reference medicinal product for which a marketing authorisation is or has been granted in the Union on the basis of a complete dossier in accordance with Articles 8(3), 10a, 10b or 10c of Directive 2001/83/EC, as amended."

The problem is that the " original" reference was withdrawn from the market ( the reason is not known but the generics are yet on the market so we suppose that was not a safety reason).



What is the solution?

a generics? But which one ( there are a plenty of them)?
a out of European marketed reference? but it's not authorised..


If you have a idea... we will take it!

Many thanks for your time!

Have a nice day

Sonia

Complete thread:

UA Flag
Activity
 Admin contact
22,557 posts in 4,724 threads, 1,607 registered users;
14 visitors (0 registered, 14 guests [including 8 identified bots]).
Forum time: 18:13 CEST (Europe/Vienna)

Science is wonderfully equipped to answer the question “How?”
but it gets terribly confused when you ask the question “Why?”    Erwin Chargaff

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5